GRCE Grace Therapeutics, Inc.: רווח נקי למניה (EPS TTM)

Grace Therapeutics, Inc. (GRCE) is collaborating with scientific funds to research therapies for pediatric neurological disorders. GURU.Markets quotes generate a chart of net profit per share over the last 12 months, where -1.22 reflects the most recent value of the metric. However, the lack of commercial cash flow and dependence on testing stages amplify risks stemming from geopolitical raw material supply disruptions and challenges regarding the protection of foreign patents.
פילוחים אנליטיים של חברת Grace Tx (GRCE)

An investment audit of the issuer requires a deep analysis of real returns prior to purchasing the asset. This metric is calculated as the ratio of total annual net income to the number of shares outstanding. For Grace Therapeutics, Inc. (GRCE), this reflects the efficiency of rare drug development and the optimization of substance supplies. Business margins directly determine the final value of this indicator. By analyzing the company's EPS TTM dynamics, an investor assesses the fundamental stability of earnings.